A Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of SAR443820 in adult participants with amyotrophic lateral sclerosis, followed by an open-label extension
The purpose of the study is to evaluate twice daily (BID) oral doses of the investigational drug SAR443820 compared to placebo (which has no active medication) in addition to the standard of care, (e.g. riluzole or edaravone) for ALS. The study will evaluate the effectiveness (how well it works) and the possible risks of taking SAR443820.
This study is currently enrolling.